Ashly E. Jordan
Research Subjects
Ashly E. Jordan has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Daniel J. Smith
New York University, Rory Meyers College of Nursing, New York, NY, USA
5 shared publications Holly Hagan
Rory Meyers College of Nursing, New York University, New York, NY, United States of America
5 shared publications- David C. Perlman
Division of Infectious Diseases, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, New York, NY, United States
4 shared publications - Holly Hagan
College of Global Public Health, New York University, 665 Broadway, 11th floor, New York, NY 10010, United States
4 shared publications - Holly Hagan
School of Global Public Health, New York University, New York, USA
4 shared publications - Samuel R. Friedman
Department of Population Health, New York University Grossman School of Medicine, New York, NY 10016, USA
4 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by SAGE Publications in Substance use & addiction journal
Policy Pathways for Addressing Opioid-Stimulant Polysubstance Use
The United States continues to grapple with the shifting substance use landscape among the emerging concurrent use of opioids and stimulants. Polysubstance use (PSU) of opioids and stimulants, whether intentionally or unintentionally, has increased substance use related morbidity and mortality. Changes at the policy level are needed to effectively curb overdose and other adverse outcomes. This article outlines 3 policy changes that are particularly relevant to opioid-stimulant PSU: (1) reforms in opioid agonist treatment policy, (2) reforms in payment for evidence-based treatment, and (3) reforms of drug paraphernalia laws. The current overdose crisis requires a multidimensional paradigm shift toward patient-centered and harm reduction focused policies that will expand access to comprehensive evidence-based treatments and services for individuals engaged in opioid and stimulant PSU.
- 19 August 2026
- Published by SAGE Publications in Substance use & addiction journal
Open AccessPolicy Pathways for Addressing Opioid-Stimulant Polysubstance Use
The United States continues to grapple with the shifting substance use landscape among the emerging concurrent use of opioids and stimulants. Polysubstance use (PSU) of opioids and stimulants, whether intentionally or unintentionally, has increased substance use related morbidity and mortality. Changes at the policy level are needed to effectively curb overdose and other adverse outcomes. This article outlines 3 policy changes that are particularly relevant to opioid-stimulant PSU: (1) reforms in opioid agonist treatment policy, (2) reforms in payment for evidence-based treatment, and (3) reforms of drug paraphernalia laws. The current overdose crisis requires a multidimensional paradigm shift toward patient-centered and harm reduction focused policies that will expand access to comprehensive evidence-based treatments and services for individuals engaged in opioid and stimulant PSU.
- Open Access
- 10 July 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (11) , 2950-2958
A comparative analysis of methodological practices used in capture–recapture population size estimation: opioid use disorder prevalence in New York State, 2020
Prevalence estimates for opioid use disorder (OUD) are essential for guiding investments in prevention and treatment. Previous estimates have been produced using modeling approaches including capture–recapture (CRC). Empirical evaluations of CRC are needed to assess population size impacts of methodological practices utilized. We linked administrative data sources including New York State (NYS) adults with OUD by indication between January 1 and December 31, 2020 and applied Bayesian CRC methods to evaluate how methodological practices impact OUD prevalence: (1) using sensitive vs specific case definition characteristics to identify OUD, (2) including vs excluding inferred referrals from emergency medical services to healthcare settings, and (3) including vs excluding overdose mortality as a source list. We estimated OUD prevalence overall and by demographic characteristics and treatment coverage with medications for OUD (MOUD). Across methodological scenarios, OUD prevalence estimates ranged from 4.6% to 9.9%. The largest estimate resulted from a model in which the more sensitive OUD case definition was applied, while the smallest resulted from a model using the more specific case definition. An estimated 4.2% of NYS adults had OUD in 2020, with 20% receiving MOUD. Findings demonstrate that CRC methodological decisions can meaningfully influence OUD prevalence estimates, with recommended methodological practices provided.
- 10 July 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (11) , 2950-2958
Open AccessA comparative analysis of methodological practices used in capture–recapture population size estimation: opioid use disorder prevalence in New York State, 2020
Prevalence estimates for opioid use disorder (OUD) are essential for guiding investments in prevention and treatment. Previous estimates have been produced using modeling approaches including capture–recapture (CRC). Empirical evaluations of CRC are needed to assess population size impacts of methodological practices utilized. We linked administrative data sources including New York State (NYS) adults with OUD by indication between January 1 and December 31, 2020 and applied Bayesian CRC methods to evaluate how methodological practices impact OUD prevalence: (1) using sensitive vs specific case definition characteristics to identify OUD, (2) including vs excluding inferred referrals from emergency medical services to healthcare settings, and (3) including vs excluding overdose mortality as a source list. We estimated OUD prevalence overall and by demographic characteristics and treatment coverage with medications for OUD (MOUD). Across methodological scenarios, OUD prevalence estimates ranged from 4.6% to 9.9%. The largest estimate resulted from a model in which the more sensitive OUD case definition was applied, while the smallest resulted from a model using the more specific case definition. An estimated 4.2% of NYS adults had OUD in 2020, with 20% receiving MOUD. Findings demonstrate that CRC methodological decisions can meaningfully influence OUD prevalence estimates, with recommended methodological practices provided.
- Open Access
- 29 May 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (6) , qxag133
Prescription stimulant consumption in the United States compared with 35 other countries
Introduction: Previous studies have identified the United States as a global outlier in stimulant prescribing. Given that stimulant prescribing in the United States has continued to increase, we aimed to provide current international comparisons. Methods: We analyzed 2024 stimulant consumption data from the International Narcotics Control Board, reported as defined daily doses for statistical purposes (S-DDD) per 1000 population per day. We compared the United States with 35 Organization for Economic Cooperation and Development members. Results: Overall, the United States comprised 26.8% of the population and consumed 67.6% of prescription stimulants. Per 1000 population per day, the United States had the second highest prescription stimulant consumption after Iceland. The volume of prescription stimulants consumed in the United States per 1000 population per day was 569% of the mean of comparison countries. Further, only 31.2% of consumed prescription stimulants in the United States was methylphenidate, vs 88.8% in comparison countries. Conclusion: Additional research is needed on the clinical and public health consequences of these major differences in controlled substance policy and clinical practice between the United States and other countries. For example, findings suggest a need to better understand any differential addictive potential of prescription stimulant regimens.
- 29 May 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (6) , qxag133
Open AccessPrescription stimulant consumption in the United States compared with 35 other countries
Introduction: Previous studies have identified the United States as a global outlier in stimulant prescribing. Given that stimulant prescribing in the United States has continued to increase, we aimed to provide current international comparisons. Methods: We analyzed 2024 stimulant consumption data from the International Narcotics Control Board, reported as defined daily doses for statistical purposes (S-DDD) per 1000 population per day. We compared the United States with 35 Organization for Economic Cooperation and Development members. Results: Overall, the United States comprised 26.8% of the population and consumed 67.6% of prescription stimulants. Per 1000 population per day, the United States had the second highest prescription stimulant consumption after Iceland. The volume of prescription stimulants consumed in the United States per 1000 population per day was 569% of the mean of comparison countries. Further, only 31.2% of consumed prescription stimulants in the United States was methylphenidate, vs 88.8% in comparison countries. Conclusion: Additional research is needed on the clinical and public health consequences of these major differences in controlled substance policy and clinical practice between the United States and other countries. For example, findings suggest a need to better understand any differential addictive potential of prescription stimulant regimens.
- 19 November 2025
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (2) , 564-569
Piloting a Point-of-Care Drug-Checking Service at Syringe Service Programs in New York City
Background: Drug checking is an evidence-based harm reduction strategy that can contribute to safer use by providing people who use drugs (PWUD) with actionable information about the contents of the drugs they are using and ways to reduce harm. In response to persistently high overdose rates largely driven by adulteration and volatility of the unregulated drug supply, the New York City Department of Health & Mental Hygiene (NYC DOHMH) initiated a point-of-care drug-checking pilot study in partnership with syringe service programs. Methods: Drug-checking services were piloted at 6 sites over the study period. DOHMH staff were trained to use immunoassay test strips and Fourier-transform Infrared Spectrometers, analyze and interpret drug-checking results, and provide tailored harm reduction education to participants. Samples were sent for secondary testing to support technician training and quality assurance. Participant demographics, information about the drug sample, and how individuals planned to use the results were collected and entered into a REDCap database. Results: From November 2021 through December 2023, more than 1600 samples were submitted for analysis. Over half of the samples were sold as opioids (55%; n = 903). The presence of fentanyl in samples sold as opioids was very high (95%; n = 859). Xylazine was detected in 35.0% (n = 201) of opioid samples for which secondary laboratory results were available. 51.5% of participants indicated that they planned to employ a harm reduction strategy or take some other action following receipt of their drug-checking results. Conclusion: Findings from the pilot study demonstrate that it is feasible and acceptable for local health departments to implement point-of-care drug-checking services in partnership with programs that serve PWUD. For some participants, drug-checking interactions may support behavioral intention changes about the drugs they use. Key implementation considerations include the importance of a robust technician training model, selection of appropriate and complementary drug-checking technologies, and availability of secondary lab testing.
- 19 November 2025
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (2) , 564-569
Piloting a Point-of-Care Drug-Checking Service at Syringe Service Programs in New York City
Background: Drug checking is an evidence-based harm reduction strategy that can contribute to safer use by providing people who use drugs (PWUD) with actionable information about the contents of the drugs they are using and ways to reduce harm. In response to persistently high overdose rates largely driven by adulteration and volatility of the unregulated drug supply, the New York City Department of Health & Mental Hygiene (NYC DOHMH) initiated a point-of-care drug-checking pilot study in partnership with syringe service programs. Methods: Drug-checking services were piloted at 6 sites over the study period. DOHMH staff were trained to use immunoassay test strips and Fourier-transform Infrared Spectrometers, analyze and interpret drug-checking results, and provide tailored harm reduction education to participants. Samples were sent for secondary testing to support technician training and quality assurance. Participant demographics, information about the drug sample, and how individuals planned to use the results were collected and entered into a REDCap database. Results: From November 2021 through December 2023, more than 1600 samples were submitted for analysis. Over half of the samples were sold as opioids (55%; n = 903). The presence of fentanyl in samples sold as opioids was very high (95%; n = 859). Xylazine was detected in 35.0% (n = 201) of opioid samples for which secondary laboratory results were available. 51.5% of participants indicated that they planned to employ a harm reduction strategy or take some other action following receipt of their drug-checking results. Conclusion: Findings from the pilot study demonstrate that it is feasible and acceptable for local health departments to implement point-of-care drug-checking services in partnership with programs that serve PWUD. For some participants, drug-checking interactions may support behavioral intention changes about the drugs they use. Key implementation considerations include the importance of a robust technician training model, selection of appropriate and complementary drug-checking technologies, and availability of secondary lab testing.
- 8 November 2024
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 19 (3) , 239-241
Leveraging Implementation Factors and Policy to Improve the Effectiveness of Naloxone
More than 50 years of high-quality data demonstrate that naloxone is an efficacious and cost-effective overdose reversal agent. Intranasal naloxone is now available in the United States as an over-the-counter and generic medication for the first time since the start of the overdose crisis more than 20 years ago. As the overdose crisis continues to contribute to substantial loss of life, there is an historic opportunity for jurisdictions to expand equitable and sustained access to intranasal naloxone. Further, through simultaneously enacting and expanding effective Naloxone Access and Good Samaritan laws, and equitably implementing these laws, there is the potential to maximize the population-level effectiveness of naloxone to sustainably reduce overdose mortality.
- 8 November 2024
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 19 (3) , 239-241
Leveraging Implementation Factors and Policy to Improve the Effectiveness of Naloxone
More than 50 years of high-quality data demonstrate that naloxone is an efficacious and cost-effective overdose reversal agent. Intranasal naloxone is now available in the United States as an over-the-counter and generic medication for the first time since the start of the overdose crisis more than 20 years ago. As the overdose crisis continues to contribute to substantial loss of life, there is an historic opportunity for jurisdictions to expand equitable and sustained access to intranasal naloxone. Further, through simultaneously enacting and expanding effective Naloxone Access and Good Samaritan laws, and equitably implementing these laws, there is the potential to maximize the population-level effectiveness of naloxone to sustainably reduce overdose mortality.
- Open Access
- 14 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0297567
Lost in transition: A protocol for a retrospective, longitudinal cohort study for addressing challenges in opioid treatment for transition-age adults
Background: In the United States, there has been a concerning rise in the prevalence of opioid use disorders (OUD) among transition-age (TA) adults, 18 to 25-years old, with a disproportionate impact on individuals and families covered by Medicaid. Of equal concern, the treatment system continues to underperform for many young people, emphasizing the need to address the treatment challenges faced by this vulnerable population at a pivotal juncture in their life course. Pharmacotherapy is the most effective treatment for OUD, yet notably, observational studies reveal gaps in the receipt of and retention in medications for opioid use disorder (MOUD), resulting in poor outcomes for many TA adults in treatment. Few current studies on OUD treatment quality explicitly consider the influence of individual, organizational, and contextual factors, especially for young people whose social roles and institutional ties remain in flux. Methods: We introduce a retrospective, longitudinal cohort design to study treatment quality practices and outcomes among approximately 65,000 TA adults entering treatment for OUD between 2012 and 2025 in New York. We propose to combine data from multiple sources, including Medicaid claims and encounter data and a state registry of substance use disorder (SUD) treatment episodes, to examine three aspects of OUD treatment quality: 1) MOUD use, including MOUD option (e.g., buprenorphine, methadone, or extended-release [XR] naltrexone); 2) adherence to pharmacotherapy and retention in treatment; and 3) adverse events (e.g., overdoses). Using rigorous analytical methods, we will provide insights into how variation in treatment practices and outcomes are structured more broadly by multilevel processes related to communities, treatment programs, and characteristics of the patient, as well as their complex interplay. Discussion: Our findings will inform clinical decision making by patients and providers as well as public health responses to the rising number of young adults seeking treatment for OUD amidst the opioid and polysubstance overdose crisis in the U.S.
- 14 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0297567
Open AccessLost in transition: A protocol for a retrospective, longitudinal cohort study for addressing challenges in opioid treatment for transition-age adults
Background: In the United States, there has been a concerning rise in the prevalence of opioid use disorders (OUD) among transition-age (TA) adults, 18 to 25-years old, with a disproportionate impact on individuals and families covered by Medicaid. Of equal concern, the treatment system continues to underperform for many young people, emphasizing the need to address the treatment challenges faced by this vulnerable population at a pivotal juncture in their life course. Pharmacotherapy is the most effective treatment for OUD, yet notably, observational studies reveal gaps in the receipt of and retention in medications for opioid use disorder (MOUD), resulting in poor outcomes for many TA adults in treatment. Few current studies on OUD treatment quality explicitly consider the influence of individual, organizational, and contextual factors, especially for young people whose social roles and institutional ties remain in flux. Methods: We introduce a retrospective, longitudinal cohort design to study treatment quality practices and outcomes among approximately 65,000 TA adults entering treatment for OUD between 2012 and 2025 in New York. We propose to combine data from multiple sources, including Medicaid claims and encounter data and a state registry of substance use disorder (SUD) treatment episodes, to examine three aspects of OUD treatment quality: 1) MOUD use, including MOUD option (e.g., buprenorphine, methadone, or extended-release [XR] naltrexone); 2) adherence to pharmacotherapy and retention in treatment; and 3) adverse events (e.g., overdoses). Using rigorous analytical methods, we will provide insights into how variation in treatment practices and outcomes are structured more broadly by multilevel processes related to communities, treatment programs, and characteristics of the patient, as well as their complex interplay. Discussion: Our findings will inform clinical decision making by patients and providers as well as public health responses to the rising number of young adults seeking treatment for OUD amidst the opioid and polysubstance overdose crisis in the U.S.
- Open Access
Housing Status and COVID-19 Prevention Recommendations among People Who Use Drugs
Housing conditions can increase health risks for people who use opioids (PWUO). Little research documents the influence of housing on PWUO’s ability to practice disease prevention methods. This study examines associations between housing status of PWUO in NYC and their ability to practice COVID-19 prevention recommendations during the initial wave of the pandemic. Participants were recruited via convenience sampling and administered a survey. Eligibility required age ≥18 years, using opioids ≥3times in the prior 30 days, and accessing a health-related service in the prior year. Descriptive and bivariate statistics assessed relationships between housing and the ability to practice social distancing, access soap and running water or hand sanitizer (soap), and access face masks. Multivariable Poisson regression was used to examine relationships between housing and the potential to practice COVID-19 prevention recommendations. The 329 participants were grouped into stable housing (34.3%), unstable/shelter housing (31.9%), and street homeless (33.7%) categories. Street homeless PWUO were significantly less likely to have access to soap and face masks than those stably housed. There were no significant differences between PWUO experiencing unstable and stable housing. PWUO experiencing street homelessness may have had increased vulnerability to COVID-19. Providing low-threshold health-related resources and increasing linkages to housing opportunities could promote health of PWUO experiencing street homelessness during future emergencies.
Open AccessHousing Status and COVID-19 Prevention Recommendations among People Who Use Drugs
Housing conditions can increase health risks for people who use opioids (PWUO). Little research documents the influence of housing on PWUO’s ability to practice disease prevention methods. This study examines associations between housing status of PWUO in NYC and their ability to practice COVID-19 prevention recommendations during the initial wave of the pandemic. Participants were recruited via convenience sampling and administered a survey. Eligibility required age ≥18 years, using opioids ≥3times in the prior 30 days, and accessing a health-related service in the prior year. Descriptive and bivariate statistics assessed relationships between housing and the ability to practice social distancing, access soap and running water or hand sanitizer (soap), and access face masks. Multivariable Poisson regression was used to examine relationships between housing and the potential to practice COVID-19 prevention recommendations. The 329 participants were grouped into stable housing (34.3%), unstable/shelter housing (31.9%), and street homeless (33.7%) categories. Street homeless PWUO were significantly less likely to have access to soap and face masks than those stably housed. There were no significant differences between PWUO experiencing unstable and stable housing. PWUO experiencing street homelessness may have had increased vulnerability to COVID-19. Providing low-threshold health-related resources and increasing linkages to housing opportunities could promote health of PWUO experiencing street homelessness during future emergencies.
- 27 August 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (5) , 1235-1239
The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination
Hepatitis C virus (HCV) elimination is an important global public health goal. However, the United States is not on track to meet the World Health Organization's 2030 targets for HCV elimination. Recently, the White House proposed an HCV elimination plan that includes point-of-care (POC) HCV RNA testing, which is currently in use in many countries but is not approved in the United States. POC HCV RNA testing is crucial for implementing community-based testing and for enabling test-and-treat programs, assessing cure, and monitoring for reinfection. Here, we review the status of POC HCV RNA testing in the United States, discuss factors that are needed for successful implementation, and issue specific public health and policy recommendations that would allow for the use of POC HCV RNA testing to support HCV elimination.
- 27 August 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (5) , 1235-1239
The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination
Hepatitis C virus (HCV) elimination is an important global public health goal. However, the United States is not on track to meet the World Health Organization's 2030 targets for HCV elimination. Recently, the White House proposed an HCV elimination plan that includes point-of-care (POC) HCV RNA testing, which is currently in use in many countries but is not approved in the United States. POC HCV RNA testing is crucial for implementing community-based testing and for enabling test-and-treat programs, assessing cure, and monitoring for reinfection. Here, we review the status of POC HCV RNA testing in the United States, discuss factors that are needed for successful implementation, and issue specific public health and policy recommendations that would allow for the use of POC HCV RNA testing to support HCV elimination.
- 13 April 2023
- Published by SAGE Publications in Criminal Justice and Behavior
- Vol. 50 (6) , 787-805
A Systematic Review and Narrative Synthesis of Interventions to Address Substance Use Disorders and Other Mental Health Disorders in Prison Settings With a Focus on Low- and Middle-Income Countries
Interventions to treat substance use disorders (SUDs) and other mental health disorders (MHDs) in prison settings vary in both availability and effectiveness across contexts. Furthermore, incomplete characterization of intervention efficacy and/or effectiveness impacts the ability to know whether an intervention with demonstrated effectiveness in one setting will be effective in another setting. We systematically reviewed the literature for studies of interventions for SUDs and other MHDs conducted in prison settings, and synthesized the identified interventions and identified evidence gaps. Search strategies yielded 9,599 articles published between January 1, 2010, and December 31, 2020. A total of 82 articles were identified as eligible with interventions presented for SUDs ( n = 52), for MHDs ( n = 23), and for SUDs/MHDs ( n = 7). Findings point to a narrow range of interventions of demonstrated effectiveness and to important gaps in the evidence-base for which high-quality research, particularly in low- and middle-income settings, is needed.
- 13 April 2023
- Published by SAGE Publications in Criminal Justice and Behavior
- Vol. 50 (6) , 787-805
A Systematic Review and Narrative Synthesis of Interventions to Address Substance Use Disorders and Other Mental Health Disorders in Prison Settings With a Focus on Low- and Middle-Income Countries
Interventions to treat substance use disorders (SUDs) and other mental health disorders (MHDs) in prison settings vary in both availability and effectiveness across contexts. Furthermore, incomplete characterization of intervention efficacy and/or effectiveness impacts the ability to know whether an intervention with demonstrated effectiveness in one setting will be effective in another setting. We systematically reviewed the literature for studies of interventions for SUDs and other MHDs conducted in prison settings, and synthesized the identified interventions and identified evidence gaps. Search strategies yielded 9,599 articles published between January 1, 2010, and December 31, 2020. A total of 82 articles were identified as eligible with interventions presented for SUDs ( n = 52), for MHDs ( n = 23), and for SUDs/MHDs ( n = 7). Findings point to a narrow range of interventions of demonstrated effectiveness and to important gaps in the evidence-base for which high-quality research, particularly in low- and middle-income settings, is needed.